Serum BLyS levels increase after rituximab as initial therapy in patients with follicular grade 1 non-Hodgkin lymphoma

被引：14

作者：

Ansell, Stephen M. ^{[1
]}

Novak, Anne J. ^{[1
]}

Ziesmer, Steven ^{[1
]}

Price-Troska, Tammy ^{[1
]}

LaPlant, Betsy ^{[2
]}

Dillon, Stacey R. ^{[3
]}

Witzig, Thomas E. ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Mayo Clin, Div Biostat, Rochester, MN 55905 USA

[3] Zymogenet Inc, Dept Autoimmun & Inflammat, Seattle, WA 98105 USA

来源：

AMERICAN JOURNAL OF HEMATOLOGY | 2009年 / 84卷 / 02期

关键词：

CHRONIC LYMPHOCYTIC-LEUKEMIA; RHEUMATOID-ARTHRITIS; AUTOIMMUNE-DISEASE; TREATED PATIENTS; TNF RECEPTOR; B-CELLS; BAFF; APRIL; SURVIVAL; FAMILY;

D O I：

10.1002/ajh.21328

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Serum B-lymphocyte stimulator (BLyS) levels are elevated in a subset of non-Hodgkin lymphoma (NHL) patients, particularly those with a family history of B-cell malignancies or a polymorphism in the BLyS gene. BLyS promotes growth of malignant B-cells and increased serum BLyS levels are associated with a poor clinical outcome. In this study, BLyS levels were measured before and after 4 weekly doses of rituximab in 30 patients with previously untreated follicular Grade 1 NHL. A significant increase was seen in the serum levels of BLyS (P = 0.0001) after rituximab therapy. The increase was independent of genetic variability in the BLyS gene. Am. J. Hematol. 84:71-73, 2009. (C) 2008 Wiley-Liss, Inc.

引用

页码：71 / 73

页数：3

共 23 条

[1] Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse [J].

Cambridge, G ;

Stohl, W ;

Leandro, MJ ;

Migone, TS ;

Hilbert, DM ;

Edwards, JCW .

ARTHRITIS AND RHEUMATISM, 2006, 54 (03) :723-732

[2] Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden:: clinical and molecular evaluation [J].

Colombat, P ;

Salles, G ;

Brousse, N ;

Eftekhari, P ;

Soubeyran, P ;

Delwail, V ;

Deconinck, E ;

Haïoun, C ;

Foussard, C ;

Sebban, C ;

Stamatoullas, A ;

Milpied, N ;

Boué, F ;

Taillan, B ;

Lederlin, P ;

Najman, A ;

Thièblemont, C ;

Montestruc, F ;

Mathieu-Boué, A ;

Benzohra, A ;

Solal-Céligny, P .

BLOOD, 2001, 97 (01) :101-106

[3] TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease [J].

Gross, JA ;

Johnston, J ;

Mudri, S ;

Enselman, R ;

Dillon, SR ;

Madden, K ;

Xu, WF ;

Parrish-Novak, J ;

Foster, D ;

Lofton-Day, C ;

Moore, M ;

Littau, A ;

Grossman, A ;

Haugen, H ;

Foley, K ;

Blumberg, H ;

Harrison, K ;

Kindsvogel, W ;

Clegg, CH .

NATURE, 2000, 404 (6781) :995-999

[4] TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: Impaired B cell maturation in mice lacking BLyS [J].

Gross, JA ;

Dillon, SR ;

Mudri, S ;

Johnston, J ;

Littau, A ;

Roque, R ;

Rixon, M ;

Schou, O ;

Foley, KP ;

Haugen, H ;

McMillen, S ;

Waggie, K ;

Schreckhise, RW ;

Shoemaker, K ;

Vu, T ;

Moore, M ;

Grossman, A ;

Clegg, CH .

IMMUNITY, 2001, 15 (02) :289-302

[5] First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphoma [J].

Hainsworth, JD .

SEMINARS IN ONCOLOGY, 2003, 30 (01) :9-15

[6] Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma [J].

Hainsworth, JD ;

Litchy, S ;

Burris, HA ;

Scullin, DC ;

Corso, SW ;

Yardley, DA ;

Morrissey, L ;

Greco, FA .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (20) :4261-4267

[7]

HALAT S, 2006, IMMUNOLOGY, V118, P281

[8] Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL [J].

He, B ;

Chadburn, A ;

Jou, E ;

Schattner, EJ ;

Knowles, DM ;

Cerutti, A .

JOURNAL OF IMMUNOLOGY, 2004, 172 (05) :3268-3279

[9] Homeostatic cell-cycle control by BLyS:: Induction of cell-cycle entry but not G1/S transition in opposition to p18INK4c and p27Kip1 [J].

Huang, XG ;

Di Liberto, M ;

Cunningham, AF ;

Lin, K ;

Cheng, SH ;

Ely, S ;

Liou, H ;

MacLennan, ICM ;

Chen-Kiang, S .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (51) :17789-17794

[10] Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production [J].

Lavie, Frederic ;

Miceli-Richard, Corinne ;

Ittah, Marc ;

Sellam, Jeremie ;

Gottenberg, Jacques-Eric ;

Mariette, Xavier .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (05) :700-703

← 1 2 3 →